The renal urodilatin system: Clinical implications

Cardiovascular Research

Volumn 51, Issue 3, 2001, Pages 450-462

  Forssmann, Wolf Georg ^a   Meyer, Markus ^a   Forssmann, Kristin ^a  

^a IPF PHARMACEUTICALS GMBH   (Germany)

Author keywords

Antihypertensive diuretic agents; Blood pressure; Heart failure; Hormones; Natriuretic peptide; Renal function; Vasoconstrition dilation

Indexed keywords

ATRIAL NATRIURETIC FACTOR; ATRIAL NATRIURETIC FACTOR ALPHA; BRAIN NATRIURETIC PEPTIDE; CYCLIC AMP; CYCLIC GMP; CYCLOSPORIN A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NATRIURETIC PEPTIDE RECEPTOR A; NATRIURETIC PEPTIDE RECEPTOR B; NATRIURETIC PEPTIDE RECEPTOR C; NATRIURETIC PEPTIDE TYPE C; NESIRITIDE; RECEPTOR; SALBUTAMOL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; URODILATIN;

ACUTE KIDNEY FAILURE; AMINO ACID SEQUENCE; ASTHMA; BIOCHEMISTRY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFECT; DRUG EFFICACY; ERECTILE DYSFUNCTION; HEPATORENAL SYNDROME; HOMEOSTASIS; HUMAN; IMMUNITY; KIDNEY COLLECTING TUBULE; KIDNEY TUBULE CELL; NEPHRON; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; SODIUM ABSORPTION; SODIUM EXCRETION; URINALYSIS; WATER ABSORPTION;

ANIMALS; ASTHMA; ATRIAL NATRIURETIC FACTOR; BRONCHODILATOR AGENTS; DIURESIS; DIURETICS; HEART FAILURE, CONGESTIVE; HUMANS; PEPTIDE FRAGMENTS;

EID: 0035882195     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(01)00331-5     Document Type: Review

References (113)

1. Diverse biological actions of atrial natriuretic peptide
2. Cardiac hormones. I. Review on the morphology, biochemistry, and molecular biology of the endocrine heart
3. Atrial natriuretic factor and related peptide hormones
4. The endocrine heart and natriuretic peptides: Histochemistry, cell biology, and functional aspects of the renal urodilatin system
5. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats
6. The amino acid sequence of an atrial peptide with potent diuretic and natriuretic properties
7. The right auricle of the heart is an endocrine organ
8. Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (alpha-hANP)
9. Bioactive cardiac substances: Potent vasorelaxant activity in mammalian atria
10. Rat atrial natriuretic factor: Purification and vasorelaxant activity
11. The auricular myocardiocytes of the heart constitute an endocrine organ. Characterization of porcine cardiac peptide hormone, cardiodilatin1-126
12. Isolation and structural analysis of 'urodilatin', a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine
13. A new natriuretic peptide in porcine brain
14. C-type natriuretic peptide (CNP): A new member of natriuretic peptide family identified in porcine brain
15. The heart is the center of a new endocrine, paracrine, and neuroendocrine system
16. Isolation and structural analysis of the circulating human cardiodilatin (alpha-ANP)
17. Cellular mechanism of release of atrial natriuretic factor
18. Ultrastructural evidence for exocytotic release of atrial natriuretic polypeptide in the rat atrial muscle with the use of the tannic acid method
19. Atrial natriuretic peptide detected by immunocytochemistry in peripheral organs of Tupaia belangeri
20. Immunocytochemical localization of atrial natriuretic peptide in the kidney, adrenal medulla, pituitary and atrium of the rat
21. Cellular localisation of atrial natriuretic factor in the human kidney
22. Urodilatin (ularitide, INN): A renal natriuretic peptide. Molecular biology and clinical importance
23. Morphology of the myoendocrine cardiac cell and extra-auricular systems producing cardiac hormones
24. Comparison of binding properties and cyclic GMP accumulation by atrial natriuretic peptides in endothelial cells
25. Urodilatin and β-ANF: Binding properties and activation of particulate guanylate cyclase
26. Human atrial natriuretic peptide receptor defines a new paradigm for second messenger signal transduction
27. A membrane form of guanylate cyclase is an atrial natriuretic peptide receptor
28. Receptors of atrial natriuretic factor
29. The guanylyl cyclase-a receptor
30. The guanylyl cyclase-b receptor
31. Atrial natriuretic peptides in humans. Production and clearance by various tissues
32. Studies on the secretion, metabolism, and action of atrial natriuretic peptide in man
33. Inactivation of atrial natriuretic factor by the renal brush border
34. Urodilatin (CDD/ANP-95-126) is not biologically inactivated by a peptidase from dog kidney cortex membranes in contrast to atrial natriuretic peptide/cardiodilatin (alpha-hANP/CDD-99-126)
35. Clearance of atrial natriuretic factor by lung, liver, and kidney in human subjects and the dog
36. Natriuretic peptides from the heart, brain, and kidney: Localization, processing, vasoactivity, and proteolytic degradation
37. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11
38. Renal actions of atrial natriuretic peptides
39. Biochemistry of the differential release, processing and degradation of cardiac and related peptide hormones
40. Comparative therapeutic and histological effects of intravenous Urodilatin or nitroprusside combined with dopamine during established acute renal failure in rats
41. 2+ by atriopeptin and 8-bromo-cyclic GMP is mediated by cyclic GMP-dependent protein kinase
42. The family of guanylyl cyclase receptors and their ligands
43. In vitro autoradiographic localization of ANP receptors in rat kidney and adrenal gland
44. Atrial peptides inhibit oxygen consumption in kidney medullary collecting duct cells
45. Characterization of ANP receptors in rabbit inner medullary collecting duct cells
46. Urodilatin (uro) binding sites in rat kidney
47. Urodilatin (Ularitide, INN): A renal natriuretic peptide
48. Natriuretic peptide receptors A and B have different cellular distributions in rat kidney
49. Renal actions of atrial natriuretic peptides
50. + conductance by natriuretic peptides: Molecular and functional studies in human proximal tubule cells
51. Urodilatin is involved in sodium homeostasis and exerts sodium-state dependent natriuretic and diuretic effects
52. Evidence that urodilatin, rather than ANP regulates renal sodium excretion
53. Reduced natriuresis during weightlessness
54. Effects of an acute saline infusion on fluid and electrolyte metabolism in humans
55. Physiology and pathophysiology of the atrial peptides
56. Long-term elevations of dietary sodium produce parallel increases in the renal excretion of urodilatin and sodium
57. Effect of water immersion on renal natriuretic peptide (urodilatin) excretion in humans
58. Urodilatin, a kidney-derived natriuretic factor, is excreted with a circadian rhythm and stimulated by saline infusion in man
59. Increase in plasma sodium enhances natriuresis in response to a sodium load unable to change plasma atrial peptide concentration
60. Freisetzung kardialer hormone bei höhenexposition
61. The effects of acute altitude exposure in Swiss highlanders and lowlanders
62. Endogenous natriuretic peptides: Effect on collecting duct function in rat kidney
63. Effects of ANP-(95-126) in dogs before and after induction of heart failure
64. Urodilatin is involved in sodium homeostasis and exerts sodium-state dependent natriuretic and diuretic effects
65. Urodilatin, a natriuretic factor from kidneys, can modify renal and cardiovascular function in men
66. Atrial natriuretic peptide in congestive heart failure in the dog: Plasma levels, cyclic guanosine monophosphate, ultrastructure of atrial myoendocrine cells, and hemodynamic, hormonal, and renal effects
67. Renal effects of A.N.F. (95-126), a new atrial peptide analogue, in dogs with experimental heart failure
68. Haemodynamic and renal effects of urodilatin in healthy volunteers
69. Haemodynamic and renal effects of urodilatin bolus injections in patients with congestive heart failure
70. Urodilatin and atrial natriuretic factor relax preconstricted isolated perfused guinea pig trachea and increase cyclic GMP
71. Type A natriuretic peptides exhibit different bronchoprotective effects in rats
72. Natriuretic Peptides: Physiology, therapeutic potential, and risk strtification in ischemic heart disease
73. Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans
74. Effect of Urodilatin on renal hemodynamics, tubular function and vasoactive hormones
75. Cardiovascular, endocrine, and renal effects of urodilatin in normal humans
76. Autocrine regulation of inducible nitric-oxide synthase in macrophages by atrial natriuretic peptide
77. Efficacy of prolonged infusion of Urodilatin [ANP-(95-126)] in patients with congestive heart failure
78. Natriuretic peptides in the treatment of heart failure
79. Early and late forms of cyclosporine nephrotoxicity: Studies in cardiac transplant recipients
80. The pathophysiology of Sandimmune (cyclosporine) in man and animals
81. Acute renal failure following cardiac transplantation with cyclosporine
82. Atrial natriuretic factor inhibits angiotensin-, norepinephrine-, and potassium-induced vascular contractility
83. Toxic acute renal failure in the rat: Effects of Diltiazem and Urodilatin on renal function
84. Urodilatin (INN:Ularitide) as a new drug for therapy of acute renal failure following cardiac surgery
85. Therapeutic use of the natriuretic peptide Ularitide in acute renal failure
86. Treatment of acute renal failure with urodilatin after unrelated bone marrow transplantation in an 18-month-old boy
87. Anaritide in acute tubular necrosis
88. Urodilatin and atrial natriuretic factor relax preconstricted isolated perfused guinea pig trachea and increase cyclic GMP
89. Type A natriuretic peptides exhibit different bronchoprotective effects in rats
90. Bronchodilating effects of natriuretic and vasorelaxant peptides compared to salbutamol in asthmatics
91. Bronchodilation using combined urodilatin-albuterol administration in asthma: A randomized, double-blind, placebo-controlled trial
92. Urodilatin
93. The hepatorenal syndrome (HRS)
94. Hepatorenal syndrome: Emerging perspectives of pathophysiology and therapy
95. Plasma levels of atrial natriuretic peptide in patients with chronic liver disease
96. Atrial natriuretic factor in cirrhotic patients with tense ascites. Effect of large-volume paracentesis
97. Human atrial natriuretic peptide (ANP) for the treatment of patients with liver cirrhosis and ascites
98. Comparison of renal actions of urodilatin and atrial natriuretic peptide
99. Renal effects of a Urodilatin infusion in patients with liver cirrhosis, with and without ascites
100. cGMP-mediated inhibition of TNF-alpha production by the atrial natriuretic peptide in murine macrophages
101. Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue
102. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial
103. Sustained hemodynamic effects of an infusion of Nesiritide (Human b-type natruretic peptide) in heart failure
104. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure
105. BNP: Pathophysiological and potential therapeutic roles in acute congestive heart failure
106. Natriuretic peptides in the treatment of heart failure
107. Comparative bioactivity of atrial and brain natriuretic peptides in an ovine model of heart failure
108. Vasodilatory effects of B-type natriuretic peptide are impaired in patients with chronic heart failure
109. Long-term administration of atrial natriuretic peptide in patients with acute heart failure